Blood-based CRC test more cost-effective than alternatives, study says

Blood-based colorectal cancer screening test Epi proColon was more cost-effective than other alternative screening options, according to a company release about a study published in the Journal of the National Cancer Institute.

Researchers compared Epi proColon to computed tomographic colonography, PillCam and Cologuard. Researchers compared clinical effectiveness through five different scenarios, including a scenario that assumed the Epi proColon missed 12 percent of advanced adenomas and 18 percent of CRC cases.

What they found:

1. Annual screening with Epi proColon had an incremental cost-effectiveness ratio of $63,253 for every quality-adjusted life year gained.

2. CTC every five years had a ratio of $1,092 and annual Cologuard screening had a ratio of $214,974.

3. Researchers used a "willingness-to-pay" threshold of $100,000 for quality-adjusted life years gained.

4. Epi proColon was more cost-effective than Cologuard in all scenarios, but the authors concluded that the best test was the "one that gets done."

More articles on physicians:
What CMS' proposal to eliminate the inpatient only list means for ASCs
21 surgery center developments costing $10M+
'We want people to understand why we're upset' — 5 surgery, specialty group leaders on CMS' proposed 2021 fee schedule

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers